Lamonica, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 241
EU - Europa 144
AS - Asia 71
AF - Africa 9
OC - Oceania 1
SA - Sud America 1
Totale 467
Nazione #
US - Stati Uniti d'America 240
SE - Svezia 46
IT - Italia 36
CN - Cina 28
SG - Singapore 21
FR - Francia 16
IN - India 15
DE - Germania 10
CM - Camerun 8
IE - Irlanda 7
GB - Regno Unito 6
ID - Indonesia 5
PL - Polonia 5
FI - Finlandia 4
GR - Grecia 3
RU - Federazione Russa 3
UA - Ucraina 3
LT - Lituania 2
AU - Australia 1
BE - Belgio 1
CA - Canada 1
CL - Cile 1
DK - Danimarca 1
HK - Hong Kong 1
IR - Iran 1
PT - Portogallo 1
TN - Tunisia 1
Totale 467
Città #
Chandler 51
Ann Arbor 17
New York 13
Singapore 13
Redmond 11
Redwood City 10
Ashburn 9
Dearborn 8
Cattolica 7
Dublin 7
Jacksonville 7
Milan 7
Beijing 6
Changsha 5
Fairfield 5
Jakarta 5
Rome 5
Wilmington 5
Boston 4
Kraków 4
Los Angeles 4
Houston 3
Lawrence 3
Nanjing 3
Paris 3
Athens 2
Boardman 2
Cambridge 2
Cupertino 2
Frankfurt am Main 2
Jiaxing 2
Kunming 2
Lancaster 2
Princeton 2
Pune 2
San Mateo 2
Seattle 2
Verona 2
Ardabil 1
Auburn Hills 1
Bordeaux 1
Bremen 1
Brussels 1
Clearwater 1
Clifton 1
Dallas 1
Edinburgh 1
Fuzhou 1
Hebei 1
Jinan 1
Leawood 1
London 1
Moscow 1
Mountain View 1
Nagold 1
Nanchang 1
Norwalk 1
Oak Park 1
Palo Alto 1
Poole 1
Rochester 1
San Diego 1
Santa Clara 1
Shenyang 1
Sovicille 1
Stanford 1
Thessaloníki 1
Tianjin 1
Toronto 1
Tunis 1
Woodbridge 1
Totale 274
Nome #
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 108
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 92
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 86
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 86
Totale 478
Categoria #
all - tutte 2.032
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.032


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202045 0 0 0 0 0 11 4 3 1 6 17 3
2020/202133 5 5 0 1 4 5 3 1 3 1 3 2
2021/202276 3 1 2 12 9 8 2 5 0 12 11 11
2022/2023120 21 18 8 23 6 10 0 15 11 1 3 4
2023/202451 5 10 1 6 2 14 3 0 0 1 5 4
2024/202538 3 6 6 4 18 1 0 0 0 0 0 0
Totale 478